Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4958638 | 0.84 | PABPC1 (0.41) | EGFRMAPTPABPC1MAPK1RAB9A | |
| SCHEMBL4954992 | 0.81 | EGFR (0.34) | EGFRMAPTPABPC1MAPK1RAB9A | |
| SCHEMBL4955900 | 0.80 | ALDH1A1 (0.42) | EGFRMAPTMAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL4958351 | 0.77 | MAPT (0.34) | EGFRMAPTPABPC1MAPK1RAB9A | |
| SCHEMBL4954966 | 0.77 | EGFR (0.34) | EGFRMAPTPABPC1MAPK1RAB9A | |
| SCHEMBL4958290 | 0.77 | EGFR (0.34) | EGFRMAPTPABPC1MAPK1RAB9A | |
| SCHEMBL4956778 | 0.77 | EGFR (0.34) | EGFRMAPTPABPC1MAPK1RAB9A | |
| SCHEMBL4958613 | 0.77 | MAPT (0.55) | EGFRMAPTPABPC1MAPK1RAB9A | |
| SCHEMBL4954958 | 0.77 | MAPT (0.34) | EGFRMAPTPABPC1MAPK1RAB9A | |
| SCHEMBL4953834 | 0.77 | EGFR (0.34) | EGFRMAPTPABPC1MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9968602-B2 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2018-05-15 | — | — | US | claimed |
| US-20140030317-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | Occhiuti & Rohlicek LLP | 2014-01-30 | — | — | US | claimed |
| US-7326690-B2 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2008-02-05 | — | — | US | claimed |
| US-20070142303-A1 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2007-06-21 | — | — | US | claimed |
| US-12246068-B2 | Enzymatically activatable peptide-redox modulator conjugates and use thereof | BRANDEIS UNIVERSITY (US) | 2025-03-11 | — | — | US | disclosed |
| WO-2018129171-A1 | ENZYMATICALLY ACTIVATABLE PEPTIDE-REDOX MODULATOR CONJUGATES AND USE THEREOF | BRANDEIS UNIVERSITY (US) | 2018-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12246068-B2 | Enzymatically activatable peptide-redox modulator conjugates and use thereof | GPX1, GPX4, ENPEP | EGFR 1247/4885MAPT 4553/4885PABPC1 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.